Mutation Analysis of ATR Variants in Breast Cancer Families
Author Information
Author(s): Francine Durocher, Yvan Labrie, Penny Soucy, Olga Sinilnikova, Damian Labuda, Paul Bessette, Jocelyne Chiquette, Rachel Laframboise, Jean Lépine, Bernard Lespérance, Geneviève Ouellette, Roxane Pichette, Marie Plante, Sean V Tavtigian, Jacques Simard
Primary Institution: Cancer Genomics Laboratory, Oncology and Molecular Endocrinology Research Centre, Centre Hospitalier Universitaire de Québec and Laval University
Hypothesis
The study aimed to assess the involvement of ATR germline mutations in breast cancer susceptibility.
Conclusion
The study found no deleterious mutations in the ATR gene but identified several sequence variants that could be useful for future association studies.
Supporting Evidence
- No germline mutations were identified in the ATR coding region.
- 41 sequence variants were identified, including 16 coding variants.
- Three coding variants were novel and not reported in public databases.
- Haplotype analysis provided a set of SNPs for future studies.
Takeaway
Researchers looked at DNA from families with breast cancer to see if changes in a gene called ATR could be linked to the disease, but they didn't find any harmful changes.
Methodology
Direct sequencing of the ATR gene was performed on DNA samples from breast cancer patients, along with linkage disequilibrium and haplotype analyses.
Limitations
The study did not identify any deleterious mutations, which may limit the understanding of ATR's role in breast cancer susceptibility.
Participant Demographics
Participants were from high-risk French Canadian breast/ovarian cancer families, with a mean age of diagnosis at 45.5 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website